Comment on Luoet al.: Diabetes mellitus and the incidence and mortality of colorectal cancer: a meta-analysis of 24 cohort studies

AbstractEpidemiologic studies have examined the possible associations between diabetes mellitus (DM) and gastric cancer (GC), but the results are inconclusive. We conducted a meta-analysis to assess the evidence regarding the associations between diabetes and incidences of, or mortality from, gastric cancer.PubMed, Embase and Web of Science were searched up to Oct 20, 2011. We identified studies that included effects estimates with 95% confidence intervals (CIs) of the associations between GC and diabetes. Summary RRs for the GC incidence and mortality were calculated using random-effects model; subgroup analyses were also performed. Heterogeneity among studies was examined using Q and I2 statistics.A total of 7 case-control and 18 cohort studies met the inclusion criteria. The summary RR showed a slightly statistical link between history of DM and GC incidence (RR=1.11, 95% CI: 1.00–1.24, p=0.045, I2=79.5%). In the subgroup analyses, a positive association was noted among the studies conducted in Asia (summary RR=1.19, 95% CI: 1.07–1.32, I2=29.8%). Additionally, slight associations between DM and GC were observed by pooling the data of type 2 DM, cohort studies and the studies controlling more confounders, respectively. Furthermore, mortality from GC with diabetes was increased compared with individuals without diabetes (summary RR=1.29, 95% CI: 1.04–1.59). No publication bias was found.Individuals with diabetes have an increased risk of developing gastric cancer, and are positively associated with gastric cancer mortality. Large better-designed cohort studies are needed to verify this conclusion.

Download Full-text

Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer

British Journal of Surgery ◽

10.1002/bjs.9229 ◽

2013 ◽

Vol 100 (11) ◽

pp. 1421-1429 ◽

Cited By ~ 106

Author(s):

K. M. J. De Bruijn ◽

L. R. Arends ◽

B. E. Hansen ◽

S. Leeflang ◽

R. Ruiter ◽

...

Keyword(s):

Diabetes Mellitus ◽

Colorectal Cancer ◽

Systematic Review ◽

Meta Analysis ◽

Incidence And Mortality

Download Full-text

Dairy Consumption and Risks of Colorectal Cancer Incidence and Mortality: A Meta-analysis of Prospective Cohort Studies

Cancer Epidemiology Biomarkers & Prevention ◽

10.1158/1055-9965.epi-20-0127 ◽

2020 ◽

Vol 29 (11) ◽

pp. 2309-2322

Author(s):

Shaoyue Jin ◽

Youngyo Kim ◽

Youjin Je

Keyword(s):

Colorectal Cancer ◽

Cohort Studies ◽

Cancer Incidence ◽

Prospective Cohort ◽

Meta Analysis ◽

Prospective Cohort Studies ◽

Dairy Consumption ◽

Incidence And Mortality ◽

Colorectal Cancer Incidence

Download Full-text

Metformin Improves Overall Survival of Colorectal Cancer Patients with Diabetes: A Meta-Analysis

Journal of Diabetes Research ◽

10.1155/2017/5063239 ◽

2017 ◽

Vol 2017 ◽

pp. 1-8 ◽

Cited By ~ 26

Author(s):

Fanqiang Meng ◽

Li Song ◽

Wenyue Wang

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Cohort Studies ◽

Meta Analysis ◽

Good Choice ◽

Cochrane Library ◽

Cancer Specific Survival ◽

Incidence And Mortality ◽

Patients With Diabetes ◽

Colorectal Cancer Patients

Introduction. Diabetic population has a higher risk of colorectal cancer (CRC) incidence and mortality than nondiabetics. The role of metformin in CRC prognosis is still controversial. The meta-analysis aims to investigate whether metformin improves the survival of diabetic CRC patients.Methods. PubMed, EMBASE, and Cochrane Library were searched till July 1, 2016. Cohort studies were included. All articles were evaluated by Newcastle-Ottawa Scale. Hazard Ratios (HRs) with 95% confidence intervals (CIs) for each study were calculated and pooled HRs with corresponding 95% CIs were generated using the random-effects model. Heterogeneity and publication bias were assessed.Results. We included seven cohort studies with a medium heterogeneity (I2= 56.1% andp=0.033) in our meta-analysis. An improved overall survival (OS) for metformin users over nonusers among colorectal cancers with diabetes was noted (HR 0.75; 95% CI 0.65 to 0.87). However, metformin reveals no benefits for cancer-specific survival (HR 0.79, 95%, CI 0.58 to 1.08).Conclusions. Metformin prolongs the OS of diabetic CRC patients, but it does not affect the CRC-specific survival. Metformin may be a good choice in treating CRC patients with diabetes mellitus in clinical settings.

Download Full-text

Diabetes Mellitus and the Occurrence of Colorectal Cancer: An Updated Meta-Analysis of Cohort Studies

Diabetes Technology & Therapeutics ◽

10.1089/dia.2012.0263 ◽

2013 ◽

Vol 15 (5) ◽

pp. 419-427 ◽

Cited By ~ 29

Author(s):

Lei Wu ◽

Chao Yu ◽

Han Jiang ◽

Jun Tang ◽

He-lang Huang ◽

...

Keyword(s):

Diabetes Mellitus ◽

Colorectal Cancer ◽

Cohort Studies ◽

Meta Analysis

Download Full-text

Non-autoimmune diabetes mellitus and the risk of virus infections: a systematic review and meta-analysis of case-control and cohort studies

Scientific Reports ◽

10.1038/s41598-021-88598-6 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Eric Lontchi-Yimagou ◽

Charly Feutseu ◽

Sebastien Kenmoe ◽

Alexandra Lindsey Djomkam Zune ◽

Solange Fai Kinyuy Ekali ◽

...

Keyword(s):

Diabetes Mellitus ◽

Systematic Review ◽

Cohort Studies ◽

H1n1 Virus ◽

Autoimmune Diabetes ◽

Meta Analysis ◽

Case Control ◽

Cochrane Central Register ◽

Virus Infections ◽

Autoimmune Diabetes Mellitus

AbstractA significant number of studies invoked diabetes as a risk factor for virus infections, but the issue remains controversial. We aimed to examine whether non-autoimmune diabetes mellitus enhances the risk of virus infections compared with the risk in healthy individuals without non-autoimmune diabetes mellitus. In this systematic review and meta-analysis, we assessed case-control and cohort studies on the association between non-autoimmune diabetes and viruses. We searched PubMed, Embase, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, and Web of Science with no language restriction, to identify articles published until February 15, 2021. The main outcome assessment was the risk of virus infection in individuals with non-autoimmune diabetes. We used a random-effects model to pool individual studies and assessed heterogeneity (I2) using the χ2 test on Cochrane’s Q statistic. This study is registered with PROSPERO, number CRD42019134142. Out of 3136 articles identified, we included 68 articles (90 studies, as the number of virus and or diabetes phenotype varied between included articles). The summary OR between non-autoimmune diabetes and virus infections risk were, 10.8(95% CI: 10.3–11.4; 1-study) for SARS-CoV-2; 3.6(95%CI: 2.7–4.9, I2 = 91.7%; 43-studies) for HCV; 2.7(95% CI: 1.3–5.4, I2 = 89.9%, 8-studies;) for HHV8; 2.1(95% CI: 1.7–2.5; 1-study) for H1N1 virus; 1.6(95% CI: 1.2–2.13, I2 = 98.3%, 27-studies) for HBV; 1.5(95% CI: 1.1–2.0; 1-study) for HSV1; 3.5(95% CI: 0.6–18.3 , I2 = 83.9%, 5-studies) for CMV; 2.9(95% CI: 1–8.7, 1-study) for TTV; 2.6(95% CI: 0.7–9.1, 1-study) for Parvovirus B19; 0.7(95% CI: 0.3–1.5 , 1-study) for coxsackie B virus; and 0.2(95% CI: 0–6.2; 1-study) for HGV. Our findings suggest that, non-autoimmune diabetes is associated with increased susceptibility to viruses especially SARS-CoV-2, HCV, HHV8, H1N1 virus, HBV and HSV1. Thus, these viruses deserve more attention from diabetes health-care providers, researchers, policy makers, and stakeholders for improved detection, overall proper management, and efficient control of viruses in people with non-autoimmune diabetes.

Download Full-text